Transpire Bio Achieves FDA Filing Acceptance for Generic Breo Ellipta, Positioning for Market Exclusivity
核心洞察
Transpire Bio (搜索)'s abbreviated new drug application (ANDA) for a generic version of Breo Ellipta has been accepted for filing by the U.S. FDA (搜索), marking a significant milestone for the company's complex generic franchise.
The company believes it was the first to file an ANDA with Paragraph IV certification under the Hatch-Waxman Act, potentially qualifying for 180 days of market exclusivity upon approval.
The generic version targets the $2.02 billion annual U.S. market for Breo Ellipta, which is indicated for maintenance treatment of asthma (搜索) and chronic obstructive pulmonary disease (搜索) (COPD (搜索)).
Transpire Bio (搜索) announced that the U.S. Food and Drug Administration has accepted for filing its abbreviated new drug application (ANDA) for fluticasone furoate and vilanterol inhalation powder, a generic version of Breo Ellipta 100/25. The Florida-based clinical-stage biopharmaceutical company believes it was the first to file an ANDA with a Paragraph IV certification under the provisions of the Hatch-Waxman Act, positioning itself for potential market exclusivity.
Market Opportunity and Regulatory Positioning
The generic version targets a substantial market opportunity, as Breo Ellipta reported U.S. annual sales of $2.02 billion in 2024, according to IQVIA data. The branded medication is indicated for the maintenance treatment of patients with asthma (搜索) and chronic obstructive pulmonary disease (搜索) (COPD (搜索)) in the United States.
Should the FDA approve Transpire Bio (搜索)'s ANDA, the company believes it will be eligible for 180 days of market exclusivity based on its first-to-file status with Paragraph IV certification. This regulatory advantage could provide significant commercial benefits in a multi-billion dollar market.
Leadership Perspectives on Development Achievement
"The FDA's acceptance of our ANDA for filing is an important achievement for our generic Breo Ellipta development program and our complex generic franchise as a whole," said Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio (搜索). "I am proud of our highly experienced team in South Florida who have worked tirelessly with world class CDMOs and other partners since the inception of Transpire Bio to achieve this important milestone. We are now one step closer to providing patients suffering from asthma (搜索) or COPD (搜索), an affordable option and improved access to this critical medication."
Dr. Abhishek Gupta, Chief Scientific Officer of Transpire Bio (搜索), emphasized the technical significance of the achievement: "This milestone represents the culmination of years of investment in the right technical competence and infrastructure and demonstrates Transpire Bio's capabilities in developing complex drug device combination products."
Broader Pipeline and Technology Platform
Beyond its generic franchise, Transpire Bio (搜索) is building a pipeline of innovative inhalation medicines across multiple therapeutic areas. The company has three assets in development for Idiopathic Pulmonary Fibrosis (搜索) (IPF (搜索)) and is also developing therapies for Pulmonary Arterial Hypertension (搜索) (PAH (搜索)), Diabetes (搜索), Obesity (搜索), Parkinson Disease Psychosis (搜索), and Glioblastoma (搜索).
The company has developed multiple proprietary inhalation technology platforms, including dry powder inhalers, soft-mist inhalers, and metered-dose inhalers. All products will be developed and manufactured in Transpire Bio (搜索)'s state-of-the-art manufacturing facilities located in South Florida.
Company Profile and Strategic Focus
Transpire Bio (搜索) Inc. is an integrated US-based, clinical-stage biopharmaceutical company headquartered in Sunrise, Florida. The company harnesses its inhaled drug delivery expertise to improve patients' lives by expanding access to important therapies and developing treatments for serious diseases where therapeutic options are significantly lacking.